McCall Walker
Interventional Cardiology · Gray, LANPI 1457705501
Payments from drug & device makers
What this record shows
The money is spread across several categories — other (47.1%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 31 manufacturers reported payments, led by Angiodynamics, Inc. at 56.7% of the total. 2025 is the largest year on record at $8,776, more than ten times the $227 reported in 2019.
Across 176 payments — averaging $109.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$11K
- Bard Peripheral Vascular, Inc.$2K
- Abbott$1K
- Philips North America LLC$1K
- Cardiva Medical, Inc.$503
- Medtronic$409
- plus $4K from 25 others
What the payments were for
- Consulting fees$1,90010%
- Travel & lodging$2191%
- Food & beverage$7,86841%
- Education$2091%
- Other$9,08347%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Angiodynamics, Inc. | 31 | $10,926 |
| Bard Peripheral Vascular, Inc. | 2 | $1,634 |
| Abbott | 10 | $1,231 |
| Philips North America LLC | 14 | $1,033 |
| Cardiva Medical, Inc. | 19 | $503 |
| Medtronic | 13 | $409 |
| Surmodics, Inc. | 8 | $406 |
| Inari Medical, Inc. | 3 | $351 |
| Novo Nordisk | 4 | $260 |
| Penumbra, Inc. | 3 | $248 |
| Biotronik Inc. | 4 | $239 |
| E.r. Squibb & Sons, L.L.C. | 16 | $234 |
| Imperative Care, Inc | 3 | $192 |
| Boston Scientific | 4 | $182 |
| Abiomed | 1 | $163 |
| Pfizer | 11 | $154 |
| Cardiovascular Systems Inc. | 1 | $148 |
| Tactile Systems Technology Inc | 2 | $145 |
| BD | 4 | $127 |
| Shockwave Medical, Inc | 1 | $124 |
| Amgen | 5 | $107 |
| W. L. Gore & Associates, Inc. | 1 | $101 |
| Kestra Medical Technology Services, Inc. | 2 | $65 |
| Novartis | 3 | $64 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $51 |
| Merck | 2 | $37 |
| Johnson & Johnson | 2 | $36 |
| Scpharmaceuticals Inc. | 2 | $33 |
| Itamar Medical Inc | 1 | $31 |
| Alnylam Pharmaceuticals Inc. | 1 | $24 |
| Terumo Medical Corporation | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Auryon Laser System 100-120 Vac$9,443
- (9520) IGT Devices Undivided$400
- FLOWTRIEVER CATHETER, S$322
- CT THROMBECTOMY SYSTEM KIT$322
- ESPRIT$290
- AlphaVac$243
- AngioVac$233
- Sublime 014 Rx PTA Balloon Dilatation Catheter$215
- Sublime Microcatheter, 018, 200cm, Straight$215
- Pounce Thrombectomy System$215
- Pounce Thrombectomy$215
- Pounce Venous Thrombectomy System$215
- ENSITE$209
- Impella$163
- Diamondback Coronary$148
- XACT$144
- SYMPHONY CATHETER$143
- Quadra Allure MP RF CRT Pacemkr$134
- Flexitouch Plus$129
- Entre Plus$129
How this compares
$19,279 in reported general payments places this provider in the 70th percentile of 171 interventional cardiology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 28 | $32,544 |
| JardianceEmpagliflozin | 25 | $28,629 |
| XareltoRivaroxaban | 20 | $21,585 |
| Repatha SureclickEvolocumab | 16 | $16,715 |
| MounjaroTirzepatide | 12 | $14,807 |
| ClopidogrelClopidogrel Bisulfate | 85 | $725 |
| Rosuvastatin Calcium | 67 | $521 |
| Losartan Potassium | 46 | $345 |
| Metoprolol Succinate | 57 | $319 |
| Doxazosin Mesylate | 15 | $272 |
| Atorvastatin Calcium | 34 | $186 |
| Carvedilol | 33 | $173 |
| Irbesartan | 14 | $168 |
| Lisinopril | 34 | $157 |
| Furosemide | 38 | $145 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $154 | $32,54428 claims |
| Johnson & JohnsonXarelto | $36 | $21,58520 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 171 interventional cardiology providers in Louisiana.
Other interventional cardiology in Gray
- Craig WalkerHouma$5M
- Denzil MoraesBaton Rouge$901K
- Ankur LodhaLafayette$640K
- Rajan PatelNew Orleans$517K
- Agostino IngraldiLafayette$315K
- Steven BaileyShreveport$305K
- James JenkinsNew Orleans$235K
- Louis SalvaggioLafayette$214K
- Pradeep NairHouma$212K
- Jorge CastellanosBaton Rouge$185K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.